Article Text

Download PDFPDF

A paclitaxel coated stent used for in-stent restenosis within a sirolimus coated stent fails to protect against recurrent restenosis
  1. A D Bainbridge,
  2. D Muir,
  3. F Fath-Ordoubadi

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The optimal approach to in-stent restenosis (ISR) within a drug eluting stent (DES) remains uncertain. The Rotterdam research registry reported a zero major adverse cardiac event (MACE) rate at a median of 131 days in 10 patients treated with a paclitaxel coated Taxus DES for ISR within a sirolimus coated Cypher DES. However, this strategy may fail to prevent recurrent ISR. A 40 year old ex-smoking white female with type 1 diabetes, renal failure, hypertension, hypercholesterolaemia, and a strong family history of premature coronary disease had inferior ischaemia on a myocardial perfusion scan and a 90% stenosis in the right coronary artery at angiography (panel A). This was predilated and stented with a 2.75 × 33 mm Cypher (panel B). Secondary prevention was optimised. Six months later angiography revealed ISR within the Cypher (panel C). This was predilated with a cutting balloon and stented with a 3.0 by 28 mm Taxus (panel D). Check angiography at eight months revealed very tight ISR in the Taxus (panel E). The implantation of a Taxus stent to treat ISR within a Cypher failed to prevent recurrent ISR.

Embedded Image